What are your prediction on prices? Obviously, these stocks and potential return in the next three years for each.

As an AI, I don't have personal opinions or the ability to predict future stock prices with certainty. However, I can provide some analysis based on the available data.

Price Predictions:

1. Aadi Bioscience (AADI): With a 3-Year Total Revenue CAGR of 1258.57% and a significant increase in net income, Aadi Bioscience shows strong potential for growth. The P/E ratio suggests that the market may be high, but the company's innovative treatments for rare diseases and the growing demand for healthcare solutions could drive future performance. Given the high revenue growth and positive industry outlook, Aadi Bioscience could potentially offer high returns over the next three years.
2. Abits Group (ABTS): Abits Group's 3-Year Total Revenue CAGR of 176.89% and improved net income indicate a strong growth trajectory. The company's involvement in the construction industry, which is expected to grow, and its low P/E ratio suggest that it may be undervalued. If the company can capitalize on industry growth and improve operational efficiency, it could offer substantial returns over the next three years.
3. Arbutus Biopharma (ABUS): Arbutus Biopharma's 3-Year Total Revenue CAGR of 28.49% and steady improvement in net income show a solid growth pattern. The biopharmaceutical sector's expected growth and the company's focus on developing treatments for chronic diseases position it well for potential high returns. However, the high P/E ratio and the competitive nature of the industry may impact its performance.
4. ProFrac Holding (ACDC): ProFrac Holding's 3-Year Total Revenue CAGR of 114.99% and significant net income growth are impressive indicators of strong performance. The energy sector, although volatile, is expected to grow, and the company's focus on water management services could present opportunities for high returns. The low P/E ratio suggests that the market may be undervaluing the company's potential.
5. Aclaris Therapeutics (ACRS): Aclaris Therapeutics' 3-Year Total Revenue CAGR of 85.01% and steady improvement in net income demonstrate a growing business. The dermatology sector's expected growth and the company's focus on innovative treatments could drive future performance. The high P/E ratio and the competitive nature of the industry may impact its returns, but the company's strong revenue growth suggests potential for high returns.

Potential Returns:

Given the strong revenue growth, improving net income, and favorable industry positions, all five stocks have the potential to offer high returns over the next three years. However, it's important to note that high-risk investments like these should be approached with caution, and thorough due diligence is recommended before making investment decisions.

The percentage returns will depend on various factors, including market conditions, company performance, and industry trends. While Aadi Bioscience and Abits Group show particularly strong growth potential, all five stocks could offer substantial returns if they can execute on their strategic plans and capitalize on industry growth.